Infant Bacterial Therapeutics AB (OSTO:IBT B) 3-Year EBITDA Growth Rate : -16.10% (As of Jun. 2024)

View and export this data going back to 2016. Start your Free Trial

What is Infant Bacterial Therapeutics AB 3-Year EBITDA Growth Rate?

Infant Bacterial Therapeutics AB's EBITDA per Share for the three months ended in Jun. 2024 was kr-3.15.

During the past 3 years, the average EBITDA Per Share Growth Rate was -16.10% per year. During the past 5 years, the average EBITDA Per Share Growth Rate was -17.80% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

During the past 10 years, the highest 3-Year average EBITDA Per Share Growth Rate of Infant Bacterial Therapeutics AB was 29.30% per year. The lowest was -47.40% per year. And the median was -8.00% per year.

Competitive Comparison of Infant Bacterial Therapeutics AB's 3-Year EBITDA Growth Rate

For the Biotechnology subindustry, Infant Bacterial Therapeutics AB's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Infant Bacterial Therapeutics AB's 3-Year EBITDA Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Infant Bacterial Therapeutics AB's 3-Year EBITDA Growth Rate distribution charts can be found below:

* The bar in red indicates where Infant Bacterial Therapeutics AB's 3-Year EBITDA Growth Rate falls into.

Infant Bacterial Therapeutics AB 3-Year EBITDA Growth Rate Calculation

This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

Infant Bacterial Therapeutics AB (OSTO:IBT B) 3-Year EBITDA Growth Rate Explanation

EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.

Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.

Infant Bacterial Therapeutics AB 3-Year EBITDA Growth Rate Related Terms

Thank you for viewing the detailed overview of Infant Bacterial Therapeutics AB's 3-Year EBITDA Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

Infant Bacterial Therapeutics AB Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Infant Bacterial Therapeutics AB (OSTO:IBT B) » Definitions » 3-Year EBITDA Growth Rate

Comparable Companies

Traded in Other Exchanges

9IB:Germany

Address

Bryggargatan 10, Stockholm, SWE, 111 21

Website

https://www.ibtherapeutics.com

Infant Bacterial Therapeutics AB is a pharmaceutical company. Its purpose is to develop and commercialize drugs for diseases affecting premature babies. Its focus is on the drug candidate IBP-9414, whose development program is designed to show a reduced incidence of necrotizing enterocolitis (NEC) and improved gastrointestinal function (SFT) when treated with IBP-9414's active substance Lactobacillus reuteri bacterial strain naturally found in human breast milk. Its portfolio also includes additional drug candidates, IBP-1016, IBP-1118 and IBP-1122. IBP1016, for the treatment of gastroschisis, is a life-threatening and rare disorder in which children are born with externalized gastrointestinal organs.

Infant Bacterial Therapeutics AB Headlines

No Headlines